8-K filing — DELCATH SYSTEMS, INC. (DCTH)
Filed: 2026-08-14 AccNo: 0001193125-26-350536 Size: 266 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Delcath Systems Doses First Patient In Phase 2 Clinical Trial Of HEPZATO
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $32
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $30 to $32.
BTIG Maintains Buy on Delcath Systems, Raises Price Target to $21
BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $17 to $21.
Delcath Systems shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 sales guidance above estimates.